Targeting TIGIT with tiragolumab

The next era in cancer immunotherapy treatment involves combining immunotherapies that can work together, and with the body's immune system, to kill cancer

Tiragolumab, a novel cancer immunotherapy, is a fully human monoclonal antibody targeting the immune checkpoint TIGIT. Simultaneous blockade of TIGIT and PD-L1 was shown to synergistically improve tumor control and to prolong survival in preclinical models.¹

The first randomized data in the anti-TIGIT landscape came from our Phase II study in mNSCLC (CITYSCAPE; NCT03563716). The study met both its primary endpoints of ORR and PFS in the ITT population.² FDA granted breakthrough therapy designation to tiragolumab + atezolizumab▼ for first-line PD-L1-high mNSCLC based on this study.

The next randomized data that we expect in an indication other than lung cancer is with SKYSCRAPER-04 (NCT04300647) in cervical cancer.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please report suspected adverse reactions to the National Health Authority in your country and/or Roche Safety contact in your country (www.roche.com and select your country). Products under investigation have not been approved for use outside of the clinical trial setting. This information is presented only for the purpose of providing an overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved purposes.
Ongoing trial in cervical cancer

Tiragolumab | SKYSCRAPER - 04

SKYSCRAPER-04 (NCT04300647): A study of tiragolumab plus atezolizumab and atezolizumab monotherapy in patients with cervical cancer

For more information, please go to https://clinicaltrials.gov/ct2/show/NCT04300647

PRIMARY ENDPOINTS
- Objective response rate (ORR)

SECONDARY ENDPOINTS
- Duration of response (DOR)
- Disease control rate (DCR)
- Progression-free survival (PFS)
- Overall survival (OS)
- Safety
- Pharmacokinetics

Phase II
- Recurrent or persistent PD-L1-positive cervical carcinoma
- 1-2 lines of prior systemic chemotherapy in the metastatic/recurrent setting

3:1 RANDOMIZATION

Tiragolumab + Atezolizumab

Treat until disease progression or loss of clinical benefit

Atezolizumab

PD-L1 = programmed death-ligand 1.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please report suspected adverse reactions to the National Health Authority in your country and/or Roche Safety contact in your country (www.roche.com and select your country).

Products under investigation have not been approved for use outside of the clinical trial setting. This information is presented only for the purpose of providing an overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved purposes.